Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

Clinical trial NCT06856213 · RECRUITING

Trial details

NCT number: NCT06856213
Sponsor: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

Start date: 2025-06-18
Primary completion: 2028-10-01
Enrollment: 65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.